Weisbord Steven D, Palevsky Paul M
VA Pittsburgh Healthcare System, Mailstop 111F-U, 7E Room 120, Pittsburgh, PA 15240, USA.
Clin J Am Soc Nephrol. 2008 Jan;3(1):273-80. doi: 10.2215/CJN.02580607. Epub 2007 Nov 7.
Contrast-induced nephropathy is one of the few preventable forms of acute kidney injury. Several pharmacologic agents have been evaluated for the prevention of contrast-induced nephropathy, yet disappointingly, few have been shown conclusively to reduce the risk for this condition. A series of studies have demonstrated that volume expansion, particularly with intravenous fluids, is an effective intervention to reduce the risk for contrast-induced nephropathy.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This article reviews the clinical trials that have assessed the role of volume expansion for the prevention of contrast-induced nephropathy.
The administration of isotonic sodium chloride before and after radiocontrast injection seems to be more protective than equivalent volumes of hypotonic saline and, when feasible, should be administered over a sustained period of time. Recent clinical trials suggested that an abbreviated regimen of intravenous sodium bicarbonate may be superior to a comparable protocol of sodium chloride. Although a small number of studies have found that volume supplementation by mouth may be effective in preventing contrast-induced nephropathy, the routine use of enteral fluids or solute in lieu of intravenous fluids in high-risk patients cannot be recommended at this time. Rather, liberal oral fluid and solute intake should complement intravenous fluid administration to minimize risk.
Future studies will be required to define clearly the optimal prophylactic intravenous fluid regimen for contrast-induced nephropathy and further delineate the independent role of oral volume expansion for the prevention of this condition.
对比剂肾病是少数可预防的急性肾损伤形式之一。已有多种药物被评估用于预防对比剂肾病,但令人失望的是,几乎没有药物被确凿证明能降低该病的风险。一系列研究表明,扩容,尤其是静脉补液,是降低对比剂肾病风险的有效干预措施。
设计、地点、参与者及测量方法:本文回顾了评估扩容在预防对比剂肾病中作用的临床试验。
在注射放射性对比剂前后给予等渗氯化钠似乎比等量的低渗盐水更具保护作用,并且在可行的情况下,应持续给药一段时间。近期的临床试验表明,静脉注射碳酸氢钠的简化方案可能优于氯化钠的类似方案。尽管少数研究发现口服补液可能有效预防对比剂肾病,但目前不建议在高危患者中常规使用肠内液体或溶质替代静脉补液。相反,应鼓励大量口服液体和溶质以补充静脉补液,从而将风险降至最低。
未来需要开展研究,以明确对比剂肾病的最佳预防性静脉补液方案,并进一步阐明口服扩容在预防该病中的独立作用。